Page last updated: 2024-08-23

paclitaxel and Retinal Neovascularization

paclitaxel has been researched along with Retinal Neovascularization in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Breen, S; Chang, Y; Coats, S; Coffman, K; Czapiga, M; Fazenbaker, C; Gingles, N; Inigo, I; Jallal, B; Lavallee, T; Leow, CC; Peterson, N; Ricketts, SA; Soukharev, S; Woods, R1

Other Studies

1 other study(ies) available for paclitaxel and Retinal Neovascularization

ArticleYear
MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    International journal of oncology, 2012, Volume: 40, Issue:5

    Topics: Angiogenesis Inhibitors; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Corrosion Casting; Dose-Response Relationship, Drug; Female; Fluorescence; HEK293 Cells; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Paclitaxel; Phosphorylation; Receptor, TIE-2; Retinal Neovascularization; Time Factors; Transfection; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays

2012